Divison of Leukemia, Department of Hematology and Hemopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Am J Hematol. 2021 Nov 1;96(11):1532-1538. doi: 10.1002/ajh.26349. Epub 2021 Oct 5.
The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood and Marrow Transplantation (EBMT) the number of MF has increased from 515 in 2014 to 748 in 2018 . This reflects the fact that HSCT is currently the only curative treatment, capable of inducing prolonged disease-free survival. Nevertheless, several problems prevent more patients from undergoing an allogeneic HSCT: we will be discussing indications for HSCT, comorbidities, splenomegaly, older age and disease phase. Donor type and stem cell source are less of a problem. Several transplant platforms exist, including different strategies for graft versus host disease (GvHD) prophylaxis, Age tailored conditioning regimens need to be implemented, to allow older and fragile patients to undergo an allogeneic HSCT.
越来越多的骨髓纤维化（MF）患者接受异基因造血干细胞移植（HSCT）：在欧洲血液和骨髓移植协会（EBMT）的分析中，MF 的数量从 2014 年的 515 例增加到 2018 年的 748 例。这反映了 HSCT 目前是唯一的治愈性治疗方法，能够诱导长期无病生存。然而，有几个问题阻止了更多的患者接受异基因 HSCT：我们将讨论 HSCT 的适应证、合并症、脾肿大、年龄较大和疾病阶段。供体类型和干细胞来源的问题较小。存在多种移植平台，包括移植物抗宿主病（GvHD）预防的不同策略，需要实施适合年龄的预处理方案，以使年龄较大和脆弱的患者能够接受异基因 HSCT。
